The European Commission has cleared Takeda Pharmaceutical Company Ltd’s proposed $62 billion takeover of Shire Plc, subject to its disposal of an investigational drug in Shire’s portfolio for the treatment of inflammatory bowel disease (IBD). The Shire compound overlaps with Entyvio, a drug marketed by Takeda for the same disease.
Takeda has offered to divest the experimental treatment, including the rights to its development, manufacture and marketing to a purchaser that would have an incentive to produce a competitor to Entyvio.
